The first and only clinically validated circulating TTMV® DNA blood test that aids in the detection of HPV-driven cancer.

A highly accurate, reliable blood test.

NavDx is the first and only clinically validated circulating tumor-tissue–modified HPV (TTMV®) DNA blood test that aids in the detection of HPV-driven cancer.

NavDx uses proprietary technology to quantify fragments of circulating TTMV HPV DNA, a unique HPV-driven cancer biomarker that cancer cells shed into the blood. This highly accurate blood test reliably uncovers the presence of HPV+ head and neck cancer across the care continuum.¹˒²˒³

This innovative and accessible blood test for HPV+ cancer helps inform clinical decisions, enabling physicians to intervene earlier, which may result in improved outcomes.¹˒³

References

Chera BS, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol. 2020;38(10):1050-1058.
Chera BS, et al. Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer. Clin Cancer Res. 2019;25(15):4682-4690.
Berger BM, et al. Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma. Clin Cancer Res. 2022 doi: 10.1158/1078-0432.CCR-22-0562.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Head and Neck Cancers. Version 2.2022